PTPRN2 and prostate cancer: Using non-permeable androgen derivatives that do not bind to iAR, namely conjugates of testosterone covalently linked to bovine serum albumin (testosterone-BSA), we have specifically shown that activation of mAR results in actin reorganization of iAR+/mAR+ LNCaP and iAR-/mAR+ DU145 prostate cancer cell lines [8,17].